Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - AccuredReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Crinetics Pharmaceuticals (CRNX) Shares Outstanding (2017 - 2025)

Crinetics Pharmaceuticals has reported Shares Outstanding over the past 9 years, most recently at $95.6 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 2.85% year-over-year to $95.6 million; the TTM value through Dec 2025 reached $95.6 million, up 2.85%, while the annual FY2025 figure was $95.6 million, 2.85% up from the prior year.
  • Shares Outstanding for Q4 2025 was $95.6 million at Crinetics Pharmaceuticals, up from $94.5 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $95.6 million in Q4 2025 and troughed at $4.8 million in Q1 2022.
  • A 5-year average of $63.8 million and a median of $60.7 million in 2023 define the central range for Shares Outstanding.
  • Biggest five-year swings in Shares Outstanding: soared 11872.92% in 2021 and later crashed 85.52% in 2022.
  • Year by year, Shares Outstanding stood at $47.6 million in 2021, then grew by 13.19% to $53.9 million in 2022, then grew by 26.54% to $68.2 million in 2023, then surged by 36.31% to $92.9 million in 2024, then increased by 2.85% to $95.6 million in 2025.
  • Business Quant data shows Shares Outstanding for CRNX at $95.6 million in Q4 2025, $94.5 million in Q3 2025, and $94.1 million in Q2 2025.